Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer

被引:1
|
作者
Coman, Magdalena M. [1 ]
Pusztai, Lajos [2 ]
Hooley, Regina [3 ]
Andreveja, Liva [3 ]
Kim, Leah [1 ]
Joshi, Nikhil [4 ]
Bersenev, Alexey [5 ]
Krause, Diane [5 ]
Park, Tristen S. [1 ,6 ]
机构
[1] Yale Univ, Yale Sch Med, Dept Surg, New Haven, CT USA
[2] Yale Univ, Yale Canc Ctr, Dept Med, New Haven, CT USA
[3] Yale Univ, Yale Sch Med, Dept Radiol & Biomed Imaging, New Haven, CT USA
[4] Yale Univ, Yale Canc Ctr, Sch Med, Dept Immunobiol, New Haven, CT USA
[5] Yale Sch Med, Dept Lab Med & Pathol, New Haven, CT USA
[6] Yale Med Sch, New Haven, CT 06510 USA
关键词
breast cancer; adoptive cell therapy; TILs; TNBC; tumor-infiltrating lymphocytes;
D O I
10.1097/CJI.0000000000000495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes (TILs) have produced long-term response in metastatic cancers. TILs have traditionally been expanded from surgically resected specimens. Ultrasound-guided core needle biopsy (CNB) is an alternative method that avoids the morbidity of surgery and have added benefits which may include patients not amenable to surgery as well as the potential to produce TILs from multiple lesions in the same patient. We assessed the ability to produce and expand TILs from primary triple-negative breast cancer tumors from CNB (n=7) and demonstrate comparable expansion, phenotype and cytokine secretion after phorbol myristate acetate-ionomycin stimulation to TILs expanded from surgery (n=6). T cell Receptor clonality and diversity were also comparable between the two cohorts throughout the TIL culture. CNB is a safe and feasible method to obtain tumor tissue for TIL generation in patients with triple-negative breast cancer.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 50 条
  • [31] A new immunochemical strategy for triple-negative breast cancer therapy
    Chih-Wei Lin
    Tianqing Zheng
    Geramie Grande
    Alex R. Nanna
    Christoph Rader
    Richard A. Lerner
    Scientific Reports, 11
  • [32] Targeted therapy for triple-negative breast cancer: Where are we?
    Duffy, Michael J.
    McGowan, Patricia M.
    Crown, John
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (11) : 2471 - 2477
  • [33] Novel therapy for locally advanced triple-negative breast cancer
    Yamada, Atsuko
    Osada, Shinji
    Tanahashi, Toshiyuki
    Matsui, Satoshi
    Sasaki, Yoshiyuki
    Tanaka, Yoshihiro
    Okumura, Naoki
    Matsuhashi, Nobuhisa
    Takahashi, Takao
    Yamaguchi, Kazuya
    Yoshida, Kazuhiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (04) : 1266 - 1272
  • [34] Systemic therapy for triple-negative breast cancer: A changing landscape
    Kessler, Alaina J.
    Sparano, Joseph A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 171
  • [35] In vitro photodynamic therapy of triple-negative breast cancer cells
    Scarbrough, Megan
    Bradshaw, Joseph E.
    Hayes, Timothy E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [36] A new immunochemical strategy for triple-negative breast cancer therapy
    Lin, Chih-Wei
    Zheng, Tianqing
    Grande, Geramie
    Nanna, Alex R.
    Rader, Christoph
    Lerner, Richard A.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [37] Simvastatin induced ferroptosis for triple-negative breast cancer therapy
    Xianxian Yao
    Ruihong Xie
    Yongbin Cao
    Jing Tang
    Yongzhi Men
    Haibao Peng
    Wuli Yang
    Journal of Nanobiotechnology, 19
  • [38] Local therapy for triple-negative breast cancer: a comprehensive review
    Grubb, William
    Young, Rebekah
    Efird, Jimmy
    Jindal, Charulata
    Biswas, Tithi
    FUTURE ONCOLOGY, 2017, 13 (19) : 1721 - 1730
  • [39] Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)
    Noor Z.S.
    Master A.
    Current Breast Cancer Reports, 2018, 10 (4) : 282 - 288
  • [40] Novel targeted therapy development in triple-negative breast cancer
    Ueno, Naoto T.
    ANNALS OF ONCOLOGY, 2021, 32 : S258 - S258